Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Joel R EisnerKirk D BeebeGregory M MayhewYoichiro ShibataYuelong GuoCarol J FarhangfarFarhang FarhangfarJoshua M UronisJill MooneyMichael V MilburnDavid M FoureauRichard L WhiteAsim AminMarcos E MillaPublished in: Cancer research communications (2022)
Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights into genomic characteristics of therapy response. This study revealed common and distinct immune-related predictive response markers for IL2 and anti-PD-1 therapy which may play a role in therapy guidance, and rational combination strategies for these agents.